115 related articles for article (PubMed ID: 6399880)
21. A comparison of cobra venom factor-induced depletion of serum C3 in eight different strains of mice.
Finnie JA; Stewart RB; Aston WP
Dev Comp Immunol; 1981; 5(4):697-701. PubMed ID: 6797851
[No Abstract] [Full Text] [Related]
22. Functional assay of C5-activating and nonactivating cobra venom factor preparations in the mouse system.
Van den Berg CW; Aerts PC; Van Dijk H
J Immunol Methods; 1990 Oct; 133(2):199-206. PubMed ID: 2230138
[TBL] [Abstract][Full Text] [Related]
23. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity.
Oishi K; Koles NL; Guelde G; Pollack M
J Infect Dis; 1992 Jan; 165(1):34-45. PubMed ID: 1727896
[TBL] [Abstract][Full Text] [Related]
24. Heparin and modified heparin inhibit complement activation in vivo.
Weiler JM; Edens RE; Linhardt RJ; Kapelanski DP
J Immunol; 1992 May; 148(10):3210-5. PubMed ID: 1578145
[TBL] [Abstract][Full Text] [Related]
25. Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice.
Cooper PD; Sim RB
Int J Cancer; 1984 May; 33(5):683-7. PubMed ID: 6724743
[TBL] [Abstract][Full Text] [Related]
26. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.
Fritzinger DC; Hew BE; Lee JQ; Newhouse J; Alam M; Ciallella JR; Bowers M; Gorsuch WB; Guikema BJ; Stahl GL; Vogel CW
Adv Exp Med Biol; 2008; 632():293-307. PubMed ID: 19025130
[TBL] [Abstract][Full Text] [Related]
27. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
Kozlov LV; Soliakov LS; Zinchenko AA
Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
[TBL] [Abstract][Full Text] [Related]
28. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation.
Müller B; Müller-Ruchholtz W
Leuk Res; 1987; 11(5):461-8. PubMed ID: 3573809
[TBL] [Abstract][Full Text] [Related]
29. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
Usami M; Ohno Y
J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
[TBL] [Abstract][Full Text] [Related]
30. Generation and characterization of transgenic mice expressing cobra venom factor.
Andrä J; Halter R; Kock MA; Niemann H; Vogel CW; Paul D
Mol Immunol; 2002 Oct; 39(5-6):357-65. PubMed ID: 12220893
[TBL] [Abstract][Full Text] [Related]
31. Activation of rabbit C3: studies of the generation of cleavage products in vitro and of their metabolism in vivo.
Peake PW; Charlesworth JA; Pussell BA
Complement Inflamm; 1991; 8(5-6):261-70. PubMed ID: 1802545
[TBL] [Abstract][Full Text] [Related]
32. Native type II collagen--induced arthritis in the rat: the effect of complement depletion by cobra venom factor.
Morgan K; Clague RB; Shaw MJ; Firth SA; Twose TM; Holt PJ
Arthritis Rheum; 1981 Nov; 24(11):1356-62. PubMed ID: 7317113
[TBL] [Abstract][Full Text] [Related]
33. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
34. Activation of vertebrate complement by Helix pomatia haemolymph.
Koch C; Nielsen HE
Dev Comp Immunol; 1984; 8(1):15-22. PubMed ID: 6562978
[TBL] [Abstract][Full Text] [Related]
35. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Vogel CW; Fritzinger DC
Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
[TBL] [Abstract][Full Text] [Related]
36. Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.
Downs-Canner S; Magge D; Ravindranathan R; O'Malley ME; Francis L; Liu Z; Sheng Guo Z; Obermajer N; Bartlett DL
Ann Surg Oncol; 2016 Feb; 23(2):655-62. PubMed ID: 26289805
[TBL] [Abstract][Full Text] [Related]
37. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
[TBL] [Abstract][Full Text] [Related]
38. The role of complement activation in tumour necrosis factor-induced lethal hepatitis.
Libert C; Wielockx B; Grijalba B; Van Molle W; Kremmer E; Colten HR; Fiers W; Brouckaert P
Cytokine; 1999 Aug; 11(8):617-25. PubMed ID: 10433810
[TBL] [Abstract][Full Text] [Related]
39. [Restoration by N alpha-(N-acetylmuramyl-L-alanyl-D-isoglutamine)-N epsilon-stearoyl-L-lysine from the decomplement state in mice induced by cobra venom factor, followed by acquisition of resistance to bacterial infections].
Okuda T; Endo N; Zen-Yoji H; Osada Y
Kansenshogaku Zasshi; 1986 Mar; 60(3):204-9. PubMed ID: 3095445
[No Abstract] [Full Text] [Related]
40. Complement 3 is involved with ventilator-induced lung injury.
Takahashi K; Saha D; Shattino I; Pavlov VI; Stahl GL; Finnegan P; Melo MF
Int Immunopharmacol; 2011 Dec; 11(12):2138-43. PubMed ID: 21979496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
